Literature DB >> 10086801

Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life.

M L Stead1, J M Brown, G Velikova, S Kaasa, F Wisløff, J A Child, E Hippe, M Hjorth, O Sezer, P Selby.   

Abstract

A multiple myeloma-specific quality-of-life questionnaire module has been designed in collaboration with the EORTC Quality-of-Life Study Group to be used in clinical trials with the EORTC QLQ-C30, a general cancer questionnaire. Strict methodology was employed to ensure thorough and appropriate development of the module. An extensive literature review was performed to identify health-related quality-of-life issues relevant to patients with multiple myeloma. Semi-structured interviews were then carried out in several European countries with health-care providers experienced in the treatment of patients with multiple myeloma, and with a group of patients with multiple myeloma, to identify the issues which were most important to patients. A questionnaire was devised from the list of issues, using a 1-week time-frame and response categories consistent with the EORTC QLQ-C30. The provisional questionnaire and the EORTC QLQ-C30 were administered to patients with multiple myeloma in each participating country with further semi-structured interviews to refine the content and design of the questionnaire. A review of the results obtained in each stage of development resulted in a 24-item myeloma-specific module, the EORTC QLQ-MY24, which assesses disease-specific symptoms and their impact on everyday life, treatment side-effects, social support, and future perspective. The module is currently undergoing further international field-testing to assess its psychometric properties.

Entities:  

Mesh:

Year:  1999        PMID: 10086801     DOI: 10.1046/j.1365-2141.1999.01206.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  21 in total

1.  Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.

Authors:  Michel Delforge; Leonard Minuk; Jean-Claude Eisenmann; Bertrand Arnulf; Letizia Canepa; Alberto Fragasso; Serge Leyvraz; Christian Langer; Yousef Ezaydi; Dan T Vogl; Pilar Giraldo-Castellano; Sung-Soo Yoon; Charles Zarnitsky; Martine Escoffre-Barbe; Bernard Lemieux; Kevin Song; Nizar Jacques Bahlis; Shien Guo; Mara Silva Monzini; Annette Ervin-Haynes; Vanessa Houck; Thierry Facon
Journal:  Haematologica       Date:  2015-03-13       Impact factor: 9.941

2.  Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional survey.

Authors:  S Acaster; S Gaugris; G Velikova; K Yong; A J Lloyd
Journal:  Support Care Cancer       Date:  2012-08-12       Impact factor: 3.603

3.  Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.

Authors:  A Keith Stewart; Meletios A Dimopoulos; Tamás Masszi; Ivan Špička; Albert Oriol; Roman Hájek; Laura Rosiñol; David S Siegel; Ruben Niesvizky; Andrzej J Jakubowiak; Jesus F San-Miguel; Heinz Ludwig; Jacqui Buchanan; Kim Cocks; Xinqun Yang; Biao Xing; Naseem Zojwalla; Margaret Tonda; Philippe Moreau; Antonio Palumbo
Journal:  J Clin Oncol       Date:  2016-11-10       Impact factor: 44.544

4.  Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study).

Authors:  Philippe Moreau; Shaji Kumar; Ralph Boccia; Shinsuke Iida; Hartmut Goldschmidt; Kim Cocks; Andrew Trigg; Anita Zahlten-Kumeli; Emre Yucel; Sumeet S Panjabi; Meletios Dimopoulos
Journal:  Leukemia       Date:  2019-05-15       Impact factor: 11.528

5.  Quality of life assessment in multiple myeloma patients undergoing dose-reduced tandem autologous stem cell transplantation.

Authors:  A Khalafallah; K McDonnell; H U Dawar; I Robertson; D Woods
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-11-28       Impact factor: 2.576

6.  Improving the assessment of quality of life in the clinical care of myeloma patients: the development and validation of the Myeloma Patient Outcome Scale (MyPOS).

Authors:  Thomas R Osborne; Christina Ramsenthaler; Stephen A Schey; Richard J Siegert; Polly M Edmonds; Irene J Higginson
Journal:  BMC Cancer       Date:  2015-04-14       Impact factor: 4.430

7.  Reliability and validity of the Greek QLQ-C30 and QLQ-MY20 for measuring quality of life in patients with multiple myeloma.

Authors:  Nick Kontodimopoulos; Alexandros Samartzis; Angelos A Papadopoulos; Dimitris Niakas
Journal:  ScientificWorldJournal       Date:  2012-08-02

Review 8.  Review of health-related quality of life data in multiple myeloma patients treated with novel agents.

Authors:  P Sonneveld; S G Verelst; P Lewis; V Gray-Schopfer; A Hutchings; A Nixon; M T Petrucci
Journal:  Leukemia       Date:  2013-06-20       Impact factor: 11.528

9.  Understanding what matters most to people with multiple myeloma: a qualitative study of views on quality of life.

Authors:  Thomas R Osborne; Christina Ramsenthaler; Susanne de Wolf-Linder; Stephen A Schey; Richard J Siegert; Polly M Edmonds; Irene J Higginson
Journal:  BMC Cancer       Date:  2014-07-09       Impact factor: 4.430

10.  The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study.

Authors:  Christina Ramsenthaler; Thomas R Osborne; Wei Gao; Richard J Siegert; Polly M Edmonds; Stephen A Schey; Irene J Higginson
Journal:  BMC Cancer       Date:  2016-07-07       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.